CRISPR Therapeutics general counsel James R. Kasinger disposes of 1,990 shares worth $119,481.19
CRSP•General Counsel James R. Kasinger sold 1,990 CRISPR Therapeutics common shares for a weighted average price of $60.0408 on Oct. 6, 2026, after exercising options at $13.62 per share.
1. Share sale
Kasinger’s directly held common shares fell to 94,784 from 96,774 after the sale. His directly held stock options declined to 81,242 following the exercise.
